SQA

DECEMBER 16, 2022

SQA Regulatory Surveillance Summary for September and October 2022. ANVISA’s Questions & Answers (Q&A) on Medical Cannabis for Clinical Investigations, 14 September 2022. ANVISA published answers to questions received during an online seminar on clinical research of medicinal cannabis held in May 2022. 30 of 2022.

FDA 40

FDA Compliance COVID-19 Licensing 40

SQA

MAY 24, 2023

ANVISA has intercepted international shipments of Batch Number C6835C3 which presented a false description of content and contained bottles in packaging in the Turkish language with expirations dates 10/2024 (bottle) and 12/2024 (secondary packaging). The document will become effective 6 months after publication (10 September 2023).

FDA 40

FDA Licensing Governance Compliance 40

SQA

FEBRUARY 26, 2024

ANVISA Publishes New Measures to Prohibit Cosmetic Products Used in Injectable Form, 10 October 2023 ANVISA published two resolutions that suspended the trade, distribution, manufacture, advertising, and use of products from PHD Cosméticos Ltda. and Biometik Indústria e Comércio de Cosméticos.

FDA 52

FDA Compliance COVID-19 Public Health 52